PMID

Data

Article Title

Organization

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.

Shandong University

Discovery of a Dual PRMT5-PRMT7 Inhibitor.

University of Toronto

Development of Macrocyclic PRMT5-Adaptor Protein Interaction Inhibitors.

Max Planck Institute of Molecular Physiology

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5?MTA Complex for the Treatment of

Mirati Therapeutics

Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.

The Broad Institute of Mit and Harvard

A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode.

Janssen Pharmaceutica

Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.

Icahn School of Medicine At Mount Sinai

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.

Epizyme

Pharmacophore-based screening of diamidine small molecule inhibitors for protein arginine methyltransferases.

University of Georgia

Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).

Merck

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.

Shanghai Institute of Materia Medica

Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.

Prelude Therapeutics

Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.

University of Jinan

Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.

Prelude Therapeutics

Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.

Sun Yat-Sen University

LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.

Lilly Research Laboratories

Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.

University of Jinan

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

Novartis Institutes For Biomedical Research